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Abstract
Background: Accurate reporting of adverse events occurring after vaccination is an important component of
determining risk-benefit ratios for vaccinations. Controversy has developed over alleged underreporting of
adverse events within U.S. military samples. This report examines the accuracy of adverse event rates recently
published for headaches, and examines the issue of underreporting of headaches as a function of civilian or military
sources and as a function of passive versus active surveillance.
Methods: A report by Sejvar et al was examined closely for accuracy with respect to the reporting of neurologic
adverse events associated with smallpox vaccination in the United States. Rates for headaches were reported by
several scholarly sources, in addition to Sejvar et al, permitting a comparison of reporting rates as a function of
source and type of surveillance.
Results: Several major errors or omissions were identified in Sejvar et al. The count of civilian subjects vaccinated
and the totals of both civilians and military personnel vaccinated were reported incorrectly by Sejvar et al. Counts
of headaches reported in VAERS were lower (n = 95) for Sejvar et al than for Casey et al (n = 111) even though
the former allegedly used 665,000 subjects while the latter used fewer than 40,000 subjects, with both using
approximately the same civilian sources. Consequently, rates of nearly 20 neurologic adverse events reported by
Sejvar et al were also incorrectly calculated. Underreporting of headaches after smallpox vaccination appears to
increase for military samples and for passive adverse event reporting systems.
Conclusion: Until revised or corrected, the rates of neurologic adverse events after smallpox vaccinated
reported by Sejvar et al must be deemed invalid. The concept of determining overall rates of adverse events by
combining small civilian samples with large military samples appears to be invalid. Reports of headaches as adverse
events after smallpox vaccination appear to be have occurred much less frequently using passive surveillance
systems and by members of the U.S. military compared to civilians, especially those employed in healthcare
occupations. Such concerns impact risk-benefit ratios associated with vaccines and weigh against making
vaccinations mandatory, without informed consent, even among military members. Because of the issues raised
here, adverse event rates derived solely or primarily from U.S. Department of Defense reporting systems,
especially passive surveillance systems, should not be used, given better alternatives, for making public health
policy decisions.
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Background
Recently, Sejvar et al [1] reviewed the U.S. Vaccine Adverse
Event Reporting System (VAERS) reports from 64,600
civilians, mostly health care workers, and from 590,400
Department of Defense (DoD) employees who had been
vaccinated against smallpox. Their stated objective was
"To determine rates and describe the clinical features of
neurologic events associated with smallpox vaccination."
The civilians had been vaccinated by the Department of
Health and Human Services (DHHS) while the DoD
employees had been vaccinated within the U.S. military
medical system. The VAERS reports had been submitted
between December 2002 and March 2004. VAERS reports
involving neurologic symptoms for 214 individuals were
analyzed, 111 for DHHS vaccinees and 103 for DoD vac-
cinees. The most common neurologic symptom reported
was headache, in 95 (44%) of the 214 cases. They con-
cluded that "During the 2002–2004 smallpox vaccination
campaign, neurologic events were generally mild and self-
limited, and no neurologic syndrome was identified at a
rate above baseline estimates."
Reviewing Sejvar et al [1], it is clear that they stated, as fact,
that they had data from (a) 64,600 DHHS vaccinees, (b)
590,400 DoD vaccinees, and (c) a total of approximately
665,000 personnel. They also stated, as fact, that a review
of all VAERS reports submitted between December 2002
and March 2004 for those 665,000 personnel yielded no
more than 95 reports involving headaches. Furthermore,
they presented data (see Table 2 in [1]) indicating a rate of
14.3 headaches "with or without other symptoms" per
100,000 vaccinations; that rate is clearly derived from
dividing 95 headaches by 665,000 vaccinations.
The risk-benefit ratios of vaccination are very important
[2-4]. Public trust depends upon accurate reporting and
interpretation of research data on adverse outcomes asso-
ciated with vaccination, especially for programs associ-
ated with bioterrorism, such as the smallpox vaccination
campaign conducted in the United States since 2002. It is
also important that public trust be maintained with
respect to adverse outcomes associated with vaccination
among military service members, who may be required to
accept mandatory vaccinations even without informed
consent.
Issues also have been raised whether rates of adverse
reports among military members or DoD employees have
tended to be underreported [5-7]. A variety of ideas have
been proposed to account for such underreporting, which
even military health experts have admitted is possible [8].
The differing age and gender compositions of civilian and
military populations have been cited, as well as general
health and access to good medical care [6]. Many military
personnel may not be available for reporting adverse
events because of pre-deployment activities [9] or because
of distant geographic location with minimal access to
reporting channels.
Reports of adverse reactions associated with the smallpox
vaccine in a number of scientific sources [8-12] were com-
pared to the facts alleged by Sejvar et al [1]. In particular,
the rates of reported headaches were considered as a func-
tion of source and type of adverse event reporting. Several
important inconsistencies were observed. However, due
to the selection of different adverse events for study, it was
not possible to compare most of the studies except with
respect to the symptom of headache. For example, using
their mixture of 665,000 civilians and military personnel,
Sejvar et al [1] considered headache, limb paresthesias,
dizziness/vertigo, limb pain, meningitis, Bell's palsy, limb
weakness, seizures, syncope/presyncope, encephalitis, tin-
nitus, Guillain-Barre syndrome, dysphagia, demyelinating
disease, brachial neuritis, and stroke as adverse events,
whereas Grabenstein & Winkenwerder [8] considered an
almost completely different set of conditions: mild, gener-
alized vaccinia, erythema multiforme, encephalitis, acute
myopericarditis, eczema vaccinatum, progressive vac-
cinia, and death, as adverse events among 450,923 mili-
tary personnel. Relevant smallpox vaccination studies that
concerned myopericarditis [13] or folliculitis [14] were
not considered here.
Type of adverse event (active versus passive) 
reporting
VAERS is a passive surveillance system used, in part, to
help detect rates of rare but serious adverse reactions to
vaccinations. However, some reports have involved active
surveillance of adverse reactions to smallpox vaccine [8-
10,12]. Using VAERS, Sejvar et al [1] identified 95 head-
aches as reported adverse events among 665,000 vacci-
nated individuals. Also using VAERS, Casey et al [11]
identified at least 110 headache cases among 38,885 civil-
ian recipients of smallpox vaccination. Using active sur-
veillance of only 526 vaccinated personnel assigned to
seven selected military organizations, Grabenstein &
Winkenwerder [8] found 95 headaches as reported
adverse events. Also using active surveillance of 680 civil-
ian volunteers for a random single-blind trial, Frey et al
[10] received reports of 294 headaches in the first six days
after smallpox vaccination, with an unspecified number
of new cases developing after six days (they reported the
number of headaches after day 6 without indicating how
many were new cases). With 936 mostly civilian subjects,
Baggs et al [12] received 266 reports of headaches within
20 days of smallpox vaccination. In a study of 1,212 U.S.
civilian DoD and military personnel who participated as
first-time vaccinees (N = 439) or re-vaccinees (N = 773) in
a trial of the use of electronic reporting of adverse events,
Olmstead et al [9] received 317 reported incidences ofBMC Medicine 2006, 4:27 http://www.biomedcentral.com/1741-7015/4/27
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headaches. Consistently, as noted in Table 1, passive
event reporting systems yielded lower rates of headache as
an adverse event than did active event reporting systems.
Source of adverse event (military versus civilian) 
reporting
Table 1 presents the percentage of headaches reported as
adverse events following smallpox vaccinations as
reported across both a variety of types of reporting (pas-
sive versus active), as discussed previously, and across a
variety of samples (military versus civilian compositions).
Within VAERS (passive) reports, Casey et al [11] found at
least 110 headaches (0.28%) among 38,885 civilians in
contrast to Sejvar et al [1] who found only 95 headaches
(0.01%) reported among their mixture of 665,000 civilian
and military personnel. Even if nearly all of the headaches
reported by Sejvar et al [1] were military personnel
related, the reporting rate in VAERS for headaches (<
0.02%) would have been much lower for military person-
nel than for civilian personnel as reported by Casey et al
[11].
Within active adverse event reporting systems, Frey et al
[10] found at least 44.2% of their civilian subjects report-
ing post smallpox vaccination headaches. In a sample of
mostly civilian subjects, Baggs et al [12] had 28.4% of sub-
jects reporting headaches. With a mix of DoD civilian and
military personnel, Olmstead et al [9] found 26.2% of
subjects reporting headaches. Using only military sub-
jects, Grabenstein & Winkenwerder [8] found 18.1%
reporting headaches after smallpox vaccination. In other
words, the larger the military composition of the subjects,
the lower was the rate of reported headaches as post-vac-
cination adverse events. The fact that all of Frey et al's [10]
subjects were primary vaccinees may account for part of
the difference between the samples, according to Sejvar et
al [15].
Factual discrepancies or errors
The Committee on Smallpox Vaccination Program Imple-
mentation [16] reported that the national smallpox vacci-
nation campaign had reached a cumulative total of
38,004 civilian smallpox vaccinations by July 25, 2003,
with only 1,575 more civilian smallpox vaccinations over
a year later, by July 31, 2004, for a total at that time of
39,579. Sejvar et al [15] reported 34,752 civilian smallpox
vaccinations between January 24 and May 2, 2003. Casey
et al [11] used 38,885 vaccinations as their baseline from
January 24, 2003 to October 31, 2003, a number that
matches closely with the Committee data [16]. Poland et
al in a March 2003 report [17] indicated a total of 40,449
civilian smallpox vaccinations as of 13 February 2004 as
well as a total of 730,580 military smallpox vaccinations
as of 4 January 2005. However, Sejvar et al [1] reported
64,600 civilian smallpox vaccinations between December
16, 2002 and March 11, 2004, with apparently 24,151
additional smallpox vaccinations in less than four weeks
between 14 February and 11 March 2004. While the time
frame for civilian smallpox vaccinations was shorter in
Sejvar et al [1] than that considered by the Committee
[16], Sejvar et al [1] reported nearly 60% more civilian
vaccinations that were otherwise officially reported, even
though Dr. John Grabenstein co-authored at least two of
the conflicting reports [1,17]. Sejvar et al [1] also reported
considerably fewer military vaccinations than Poland et al
[17], raising questions about the number of military vac-
cinations cited in Sejvar et al [1]. Furthermore, they added
their 64,600 civilian vaccines to their 590,400 military
vaccinees, obtaining a total of 665,000 vaccines, though
their actual sum was short of 665,000 by exactly 10,000
subjects. Such errors are critical because they factored
both 665,000 and 64,600 into their computations of inci-
dence rates, as reported in their manuscript (see Table 2 in
[1]), for not only headaches, but also for 18 other neuro-
logic syndromes. It must be noted that both of the co-
authors of the Sejvar et al [1] report who reviewed this
comment admitted in their reviews that the 64,600 figure
was incorrect and should have been approximately
40,000.
Furthermore, Sejvar et al [1] reported only 95 VAERS
headache reports from among all 665,000 subjects, even
though, using a far smaller data set including most of the
same civilian subjects, Casey et al [11] had found at least
110 headaches reported as adverse events in VAERS. Sejvar
et al [1] should have found at least as many headaches as
Casey et al [11] because both their time frame and their
number of civilian subjects were larger; in addition, they
should have located many additional headache reports,
given the percentage of headaches noted elsewhere by
Olmstead et al [9] and by Grabenstein & Winkenwerder
[8] among military personnel.
The scientific validity of the article by Sejvar et al [1] has
probably been compromised by several errors. First, their
estimate of 64,600 civilian vaccinations is much larger
than the approximately 40,000 estimated from other
sources concerning the 2002–2004 smallpox vaccination
Table 1: Variation in headache rates as a function of type of 
adverse event reporting and of type of sample
Type of Adverse Event Reporting
Type of Sample Passive Active
Military < 0.016% [1] 18.1% [8]
Mixed Military and Civilian 0.014% [1] 26.2% [9]
Mostly Civilian - 28.4% [12]
Civilian 0.283% [11] 44.2% [10]
Sources are indicated in brackets after each percentage.BMC Medicine 2006, 4:27 http://www.biomedcentral.com/1741-7015/4/27
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campaign [11,16,17], unless they were counting over
24,000 vaccinations provided that had not been officially
reported along with those 40,000. Second, their addition
of 64,600 civilian and 590,400 military vaccinees should
have totalled to 655,000 rather than 665,000, unless there
is an unexplained source of the additional 10,000 vaccina-
tions. Third, of course, is that if the count of 64,600 civil-
ians is incorrect, then the total should have been closer to
630,400 rather than 665,000. Fourth, it is not clear how
Sejvar et al [1] counted only 95 headaches among VAERS
reports for 665,000 subjects, when Casey et al [11], using
the same civilian subjects but a total pool of subjects of
less than 40,000, was able to identify a greater number
(111) of headache reports in VAERS. Fifth, if their count-
ing of VAERS headaches is incorrect and their total
number of cases is incorrect, then their rates of a variety of
adverse events are, by consequence, also incorrect. Essen-
tially, such a large number of substantial errors or omis-
sions can do little except to undermine the stated
objective of Sejvar et al's [1] report, which was, as noted
before, to "determine rates and describe the clinical fea-
tures of neurologic events associated with smallpox vacci-
nation," as well as raising questions about the factual
validity of their conclusion that "During the 2002–2004
smallpox vaccination campaign, neurologic events were
generally mild and self-limited, and no neurologic syn-
drome was identified at a rate above baseline estimates."
Given our observation that military samples, whether
using active or passive reporting of adverse events follow-
ing smallpox vaccination, tend to report fewer adverse
events than civilian samples, their process of combining a
relatively small civilian sample with a far larger military
sample is also probably suspect in terms of generating
accurate rates of adverse events, even if the numbers of
civilian and military vaccines had been correct or were to
be adjusted to correct values. The publishing of such
uncorrected errors and weak methodologies by officials,
most of whom are employed full-time by the U.S. govern-
ment and/or the U.S. military, in pre-eminent medical
journals, such as JAMA, does not contribute to public trust
in the U.S. government's current approach to vaccination
programs that were designed by public policy and law, at
taxpayer expense, to support international efforts to coun-
ter the threat of bioterrorism. The scientific value of the
research reported by Sejvar et al [1] has probably been
compromised to such an extent that the article should
either be retracted or the errors or omissions of fact and
computation should be corrected throughout their report.
Despite logical protest by Grabenstein [6], Nass [5]
appears to be correct in her assertion that military subjects
have tended to underreport adverse events associated with
smallpox vaccination, relative to civilian populations, as
clearly shown in Table 1. Assuming that our assertions are
valid with respect to smallpox vaccination within the U.S.
military, underreporting of adverse symptoms associated
with other controversial vaccinations, such as anthrax vac-
cination, is almost certain. Such underreporting has
important implications for determining accurate risk-ben-
efit ratios associated with vaccination [2-4]. Along with
the types of errors presented here, uncertainty with respect
to risk-benefit ratios weighs against making higher risk
vaccinations mandatory, without informed consent, even
for military service members, especially when there are
legitimate research questions about adverse side effects of
vaccination [3], including long-term effects [18]
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